AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2022 ) > List of Articles


Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy

Parminder Singh, Manavdeep Kaur, Dinesh Kumar, Harsimran Kaur

Keywords : Ankylosing spondylitis, Pott's spine, Tofacitinib

Citation Information : Singh P, Kaur M, Kumar D, Kaur H. Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy. Curr Trends Diagn Treat 2022; 6 (2):37-38.

DOI: 10.5005/jp-journals-10055-0140

License: CC BY-NC 4.0

Published Online: 21-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton and peripheral joints. It is immune-mediated common in the second and third decades having symptoms such as sacroiliitis, synovitis, and difficulty in movement of the spine. It is treated with non-steroidal anti-inflammatory drugs (NSAIDs), JAK 2 inhibitors, and other biologicals such as infliximab and etanercept. This is the case report of a 24-year-old male student who presented with lower backache, and morning stiffness which improved with activity. On investigation, his HLA B 27 was positive and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were raised. He was treated with tofacitinib for 1 year, later he developed pott's spine as its side effect. This case report represents the rare side effect of tofacitinib as pott's spine.

  1. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014;91:47–55. DOI: 10.3899/jrheum.140102.
  2. Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology 2014;53(10):1872–1885. DOI: 10.1093/rheumatology/keu172.
  3. Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: Data from clinical trials and national registries. J Rheumatol Suppl 2014;91:56–64. DOI: 10.3899/jrheum.140103.
  4. McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ 2006;333(7568):581–585. DOI: 10.1136/bmj.38954. 689583.DE.
  5. Hammitzsch A, Lorenz G, Moog P. Impact of Janus kinase inhibition on the treatment of axial spondyloarthropathies. Front Immunol 2020;11:591176. DOI: 10.3389/fimmu.2020.591176.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.